-

Toku joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

American Heart Association consortium advances development of evidence-based health tech solutions

SAN DIEGO--(BUSINESS WIRE)--Toku Inc, a provider of an AI-based screening tool for detection of cardiovascular risk through retinal imaging, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

The Innovators’ Network is a health care technology consortium that connects entrepreneurs, providers, researchers, and payers. Innovators’ Network members also have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.

“The Center aims to advance the rapid, efficient, and effective development of healthcare technology,” said Robert A. Harrington, M.D., FAHA, volunteer past president of the American Heart Association (2019-2020), chair of the American Heart Association’s Health Tech Advisory Group for the Center and the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”

“Being a part of this network of innovators is a pivotal step in our journey to make AI-driven retinal imaging for cardiovascular risk detection available to patients globally. It enables us to accelerate the development of evidence-based, digital health solutions aimed at enhancing accessible healthcare. I am personally committed to seizing this opportunity to drive innovation and contribute significantly to our shared goal of revolutionizing healthcare accessibility.” Associate Professor Ehsan Vaghefi, CEO of Toku Inc.

About Toku Inc

Toku Inc’s CLAiR, is an AI screening tool developed to identify people with elevated ASCVD risk through retinal imaging, as part of a routine eye exam. Toku’s Series A financing was co-led by National Vision, Inc., one of the largest optical retailers in the United States, and Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community. This investment is an example of how National Vision is committed to help make technology available to everyone to see better and live better, while bridging the gap between eye care providers and primary care.

Toku is a cutting-edge technology company specializing in AI-powered diagnostic and screening tools using retinal imaging. Its flagship product, CLAiR, measures the ASCVD risk score during a routine eye health check. Toku is partnering with industry leaders like National Vision, Topcon Healthcare, and the American Heart Association Center for Health Technology & Innovation to make advanced healthcare accessible worldwide. Together, we aim to transform healthcare through innovation and data-driven solutions.

Contacts

MEDIA:
Toku Inc
Francesca Logan
Francesca.logan@tokueyes.com

Toku Inc


Release Versions

Contacts

MEDIA:
Toku Inc
Francesca Logan
Francesca.logan@tokueyes.com

More News From Toku Inc

Toku welcomes Dr Robert Weinreb to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Toku is pleased to announce the appointment of Robert N. Weinreb MD to its Board of Directors. Renowned globally for his contributions to ophthalmology, Dr. Weinreb's appointment underscores Toku's commitment to excellence and innovation in eye care. “We are thrilled to welcome Dr. Weinreb to our Board! Working with him, we will accelerate our leadership in healthcare through the eye,” according to Ehsan Vaghefi, President and CEO. Dr. Weinreb's distinguished career...

Toku Inc. Secures FDA Breakthrough Designation for Technology that Identifies Chronic Kidney Disease Risk Through the Eye

SAN DIEGO--(BUSINESS WIRE)--Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology. MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes. Most people with diabetes are not routinely screened for CKD today, resulting in the di...

Toku Appoints Former Google Head of Cardiovascular Health as Chief Health Officer

SAN DIEGO--(BUSINESS WIRE)--Toku is delighted to announce the appointment of Professor Michael V. McConnell, MD, MSEE to the role of Chief Health Officer. Professor McConnell’s former roles include Director of Advanced Cardiovascular Imaging and Preventive Cardiology at Stanford University and Head of Cardiovascular Health Innovations at Google. He is also a founding member of the American Heart Association’s Health Tech Advisory Group and author of Fight Heart Disease Like Cancer. Professor Mc...
Back to Newsroom